Cargando…

Systematic review of available evidence on 11 high-priced inpatient orphan drugs

BACKGROUND: Attention for Evidence Based Medicine (EBM) is growing, but evidence for orphan drugs is argued to be limited and inferior. This study systematically reviews the available evidence on clinical effectiveness, cost-effectiveness and budget impact for orphan drugs. METHODS: A systematic rev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanters, Tim A, de Sonneville-Koedoot, Caroline, Redekop, W Ken, Hakkaart, Leona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751719/ https://www.ncbi.nlm.nih.gov/pubmed/23947946 http://dx.doi.org/10.1186/1750-1172-8-124

Ejemplares similares

Orphan drugs expenditure in the Netherlands in the period 2006–2012
por: Kanters, Tim A, et al.
Publicado: (2014)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
por: Kanters, Tim A, et al.
Publicado: (2014)

The impact of early phase price agreements on prices of orphan drugs
por: Nuijten, Mark, et al.
Publicado: (2021)

The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan
por: Kawakami, Akihiko, et al.
Publicado: (2022)

Establishing a reasonable price for an orphan drug
por: Berdud, Mikel, et al.
Publicado: (2020)

Pricing of orphan drugs in oncology and rare diseases
por: Nuijten, Mark, et al.
Publicado: (2020)

A conceptual disease model for adult Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2015)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)

Orphan Drug Pricing: An Original Exponential Model Relating Price to the Number of Patients
por: Messori, Andrea
Publicado: (2016)

Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011)

A comparative study of orphan drug prices in Europe
por: Young, Katherine Eve, et al.
Publicado: (2017)

Variables affecting pricing of orphan drugs: the Italian case
por: Jommi, Claudio, et al.
Publicado: (2021)

Shining a light in the black box of orphan drug pricing
por: Picavet, Eline, et al.
Publicado: (2014)

Determinants of orphan drugs prices in France: a regression analysis
por: Korchagina, Daria, et al.
Publicado: (2017)

Assessment of the availability of repurposed orphan drugs in India
por: Rajueni, Khujith, et al.
Publicado: (2023)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2017)

Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union
por: Żelewski, Paweł, et al.
Publicado: (2022)

Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi
por: Hollis, Aidan
Publicado: (2019)

The availability and affordability of orphan drugs for rare diseases in China
por: Gong, Shiwei, et al.
Publicado: (2016)

Employment and the associated impact on quality of life in people diagnosed with schizophrenia
por: Bouwmans, Clazien, et al.
Publicado: (2015)

FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
por: Michaeli, Thomas, et al.
Publicado: (2023)

Evaluating Drug Prices, Availability, Affordability, and Price Components: Implications for Access to Drugs in Malaysia
por: Babar, Zaheer Ud Din, et al.
Publicado: (2007)

Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison
por: Lee, Jong Hyuk
Publicado: (2021)

In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era
por: Brouwer, Werner, et al.
Publicado: (2021)

Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
por: Dane, Aniek, et al.
Publicado: (2023)

Direct versus Indirect Treatment for Preschool Children who Stutter: The RESTART Randomized Trial
por: de Sonneville-Koedoot, Caroline, et al.
Publicado: (2015)

A qualitative study on the views of experts on the social impact of the high-priced orphan drug nusinersen
por: Rosenberg, Sara, et al.
Publicado: (2023)

Price, Availability, and Youth Obesity: Evidence From Bridging the Gap
por: Chaloupka, Frank J., et al.
Publicado: (2009)

Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe
por: Medic, Goran, et al.
Publicado: (2017)

Update of the Dutch manual for costing studies in health care
por: Kanters, Tim A., et al.
Publicado: (2017)

Orphans in the Market: The History of Orphan Drug Policy
por: Mikami, Koichi
Publicado: (2019)

Price, availability and affordability of medicines
por: Mhlanga, Brenda S., et al.
Publicado: (2014)

Registries for orphan drugs: generating evidence or marketing tools?
por: Hollak, Carla E. M., et al.
Publicado: (2020)

Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
por: Kolasa, Katarzyna, et al.
Publicado: (2016)

Orphan Drug Prices and Epidemiology of Rare Diseases: A Cross-Sectional Study in Italy in the Years 2014–2019
por: Villa, Federico, et al.
Publicado: (2022)

Antiepileptic Drug Prices, Availability and Affordability in a Resource-Limited Setting
por: Singh, Karan, et al.
Publicado: (2020)

Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic
por: Huls, Samare P. I., et al.
Publicado: (2021)

Prices, availability and affordability of medicines in Rwanda
por: Bizimana, Thomas, et al.
Publicado: (2020)

Effectiveness, safety and costs of orphan drugs: an evidence-based review
por: Onakpoya, Igho J, et al.
Publicado: (2015)

Estimating the clinical cost of drug development for orphan versus non-orphan drugs
por: Jayasundara, Kavisha, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3apj0o7t4obd94mippted0erme